Skip to main content
Equibles

Robert Finizio

Board Member

TherapeuticsMD, Inc. (TXMD)

CEO

TherapeuticsMD, Inc. (TXMD)

Equibles does not estimate personal net worth.

Get an email with a short summary when TherapeuticsMD, Inc. publishes a filing, an earnings call transcript or a press release.

Get TXMD alerts

About Robert Finizio

Robert Finizio is recorded as Board Member and CEO at TherapeuticsMD, Inc. (TXMD). The proxy statement of TherapeuticsMD, Inc. reports total compensation of $2,746,536 for Robert Finizio in fiscal 2020, including a base salary of $600,000. Disclosed compensation is on record for 4 fiscal years. Robert Finizio has spoken on 4 earnings calls across 1 company, most recently for TherapeuticsMD, Inc. on March 2, 2021. TherapeuticsMD, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at TherapeuticsMD, Inc. includes Brian Bernick (CEO), Mark Glickman (CEO), Marlan D. Walker (CEO and General Counsel) and 7 others.

Robert Finizio on recent calls

“On today's call, we will review our fourth quarter and full year performance, progress made on strengthening our capital structure, and our commercial plans. We delivered a strong year and a strong quarter with record total net product revenue for our company.”
CEO, TherapeuticsMD, Inc. Q4 FY2020 Earnings Call ·
“On today's call, we will review our third quarter performance, our future commercial plans, as well as progress made on strengthening our capital structure. Presenting on the call will be James D’Arecca, our Chief Financial Officer; and Dawn Halkuff, our Chief Commercial Officer.”
CEO, TherapeuticsMD, Inc. Q3 FY2020 Earnings Call ·
“I’ll open this morning’s call with a strategic overview, then turn the call over to James to provide an update on the agreement that we reached with Sixth Street to amend our revenue covenants and our financial results for the quarter.”
CEO, TherapeuticsMD, Inc. Q2 FY2020 Earnings Call ·
“On this morning's call, I will start with a strategic overview, review Q1 financial results and performance metrics, our strategic plan to successfully navigate COVID-19 and our approach to return to our pre-COVID-19 revenue trajectory, putting us on the path to reach EBITDA breakeven in 2021.”
CEO, TherapeuticsMD, Inc. Q1 FY2020 Earnings Call ·

Affiliation history

Company network

Leadership on record at TherapeuticsMD, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2020 TherapeuticsMD, Inc. (TXMD) $600,000 $2,746,536
2019 TherapeuticsMD, Inc. (TXMD) $600,000 $1,222,220
2018 TherapeuticsMD, Inc. (TXMD) $600,000 $2,724,577
2017 TherapeuticsMD, Inc. (TXMD) $600,000 $2,983,955

Recent activity